Esperion director granted 79,873 shares

THOMPSON JOHN CRAIG reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

THOMPSON JOHN CRAIG reported acquisition or exercise transactions in this Form 4 filing.

Esperion Therapeutics director John Craig Thompson received an equity award of 79,873 shares of common stock as compensation. The award was granted at no cash cost per share and represents his entire reported direct holding after the transaction. These shares vest in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.

Insights

Equity compensation analyst

Routine director stock grant with time-based vesting, not an open-market trade.

Director John Craig Thompson received 79,873 shares of Esperion Therapeutics common stock as a grant, with a reported price of $0.00 per share. The transaction is coded as a grant or award acquisition, indicating compensation rather than a market purchase.

The award vests in full on the earlier of May 28, 2027 or the issuer’s next annual stockholder meeting following May 28, 2026. Because this is a standard equity grant with time-based vesting and no accompanying sales, it carries limited information about the director’s view of the stock.

Insider Trade Summary

Grant/Award: 79,873 shares

Grant/Award 1 txn

Insider THOMPSON JOHN CRAIG

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	79,873	$0.00	$0.00

Holdings After Transaction: Common Stock — 79,873 shares (Direct)

Footnotes (1)

1. F1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Key Figures

Shares granted: 79,873 shares Grant price: $0.00 per share Shares held after grant: 79,873 shares +2 more

5 metrics

Shares granted 79,873 shares Common stock grant to director on May 28, 2026

Grant price $0.00 per share Reported transaction price for equity award

Shares held after grant 79,873 shares Total direct common stock holdings post-transaction

Vesting date outside meeting May 28, 2027 Latest possible full vesting date for award

Alternative vesting trigger Next annual meeting after May 28, 2026 Earlier vesting condition for the award

Key Terms

Grant, award, or other acquisition, vesting, annual meeting of stockholders

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"The awards vest in full on the earlier of (i) May 28, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders regulatory

"the Issuer's next annual meeting of stockholders following May 28, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Esperion Therapeutics (ESPR) director John Craig Thompson report in this Form 4?

John Craig Thompson reported receiving a grant of 79,873 shares of Esperion Therapeutics common stock. The filing characterizes it as a grant, award, or other acquisition for compensation, rather than an open-market purchase or sale of existing shares.

How many Esperion Therapeutics (ESPR) shares did John Craig Thompson receive and at what price?

He received 79,873 shares of Esperion Therapeutics common stock at a reported price of $0.00 per share. This reflects an equity compensation grant, not a cash purchase, and brings his directly held common stock position to 79,873 shares after the transaction.

When do John Craig Thompson’s newly granted ESPR shares vest?

The 79,873-share award vests in full on the earlier of May 28, 2027, or Esperion Therapeutics’ next annual meeting of stockholders following May 28, 2026. Until vesting, the shares are subject to this time-based service condition described in the filing footnote.

Is John Craig Thompson’s Form 4 transaction in ESPR an open-market buy or sell?

The Form 4 classifies the transaction as a grant, award, or other acquisition, not an open-market buy or sell. It records an equity compensation award of 79,873 shares at $0.00 per share, which is typical for director or executive stock grants.

How many Esperion Therapeutics (ESPR) shares does John Craig Thompson hold after this grant?

Following the reported grant, his directly held position is 79,873 shares of Esperion Therapeutics common stock. The filing does not show additional derivative holdings, so this award constitutes the full common stock position disclosed for him in this specific Form 4.

What does the vesting condition in John Craig Thompson’s ESPR stock award mean?

The vesting condition means the 79,873-share award becomes fully owned either on May 28, 2027, or at the next Esperion stockholders’ annual meeting after May 28, 2026, whichever occurs first. Before vesting, the shares remain subject to this service-based requirement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

THOMPSON JOHN CRAIG

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		79,873(1)	A	$0	79,873	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)